Perspective Therapeutics, Inc. (CATX) Stock Price

CATXStock

$2.17−54.32%52W

Market Cap$247.71M

P/E—

PEG Ratio—

Div yield—

Beta1.88

CATX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-58.85%

Price vs S&P 500 (4W)-25.61%

VGM Score23.51

Book Value / Share (Quarterly)$2.84

P/TBV (Annual)1.22x

Revenue Growth (3Y)-37.09%

Cash Flow / Share (Quarterly)$-1.06

Price vs S&P 500 (YTD)-33.02%

Gross Margin (TTM)22.97%

Net Profit Margin (TTM)-28467.97%

EPS (TTM)$-1.33

10-Day Avg Trading Volume1.81M

EPS Excl Extra (TTM)$-1.33

Revenue Growth (5Y)-38.50%

EPS (Annual)$-1.40

ROI (Annual)-49.42%

Gross Margin (Annual)23.10%

Net Profit Margin (5Y Avg)-4127.01%

Cash / Share (Quarterly)$2.08

Revenue Growth QoQ (YoY)-72.07%

ROA (Last FY)-38.63%

Revenue Growth TTM (YoY)-66.88%

EBITD / Share (TTM)$-1.30

ROE (5Y Avg)-32.85%

Operating Margin (TTM)-30619.07%

Cash Flow / Share (Annual)$-1.28

P/B Ratio0.76x

P/B Ratio (Quarterly)1.20x

Net Income / Employee (Annual)$-632,600

EV / Revenue (TTM)491.00x

Net Interest Coverage (TTM)-3.35x

ROA (TTM)-34.13%

EPS Incl Extra (Annual)$-1.40

Current Ratio (Annual)5.17x

Quick Ratio (Quarterly)6.49x

3-Month Avg Trading Volume1.80M

52-Week Price Return-54.32%

Revenue / Employee (TTM)$2,500

Tangible BV / Share (Quarterly)$2.49

P/S Ratio (Annual)280.21x

Asset Turnover (Annual)0.00x

52-Week High$6.16

Operating Margin (5Y Avg)-4448.67%

EPS Excl Extra (Annual)$-1.40

CapEx CAGR (5Y)99.28%

26-Week Price Return-48.94%

Quick Ratio (Annual)5.08x

13-Week Price Return-27.42%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)6.61x

Enterprise Value$200.82M

Revenue / Share Growth (5Y)-34.13%

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$5,400

Inventory Turnover (Annual)5.19x

Pretax Margin (Annual)-11813.12%

Cash / Share (Annual)$1.95

3-Month Return Std Dev67.46%

Gross Margin (5Y Avg)42.29%

Net Income / Employee (TTM)$-714,300

ROE (Last FY)-49.81%

Net Interest Coverage (Annual)-2.38x

EPS Basic Excl Extra (Annual)$-1.40

Receivables Turnover (TTM)1.66x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.33

Receivables Turnover (Annual)14.49x

ROI (TTM)-41.32%

P/S Ratio (TTM)605.65x

Pretax Margin (5Y Avg)-4083.08%

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$2.25

Price vs S&P 500 (52W)-69.85%

Year-to-Date Return-21.09%

5-Day Price Return-13.89%

EPS Normalized (Annual)$-1.40

ROA (5Y Avg)-26.66%

Net Profit Margin (Annual)-11665.27%

Month-to-Date Return-21.09%

Cash Flow / Share (TTM)$-0.06

EBITD / Share (Annual)$-1.49

Operating Margin (Annual)-12846.61%

LT Debt / Equity (Annual)0.01x

ROI (5Y Avg)-32.46%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.33

P/TBV (Quarterly)1.37x

P/B Ratio (Annual)0.99x

Inventory Turnover (TTM)4.82x

Pretax Margin (TTM)-28710.02%

Book Value / Share (Annual)$2.79

Price vs S&P 500 (13W)-30.11%

Beta1.88x

Revenue / Share (TTM)$0.00

ROE (TTM)-41.56%

52-Week Low$1.96

vGradeD

gGradeF

mGradeD

vgmGradeD

CATX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 10, 2026	-$0.27	-$0.22	+19.03%(+$0.05)
Q1 2026	May 11, 2026	-$0.32	-$0.25	+21.69%(+$0.07)
Q4 2025	Mar 16, 2026	-$0.34	-$0.51	-47.06%(-$0.16)
Q3 2025	Nov 10, 2025	-$0.32	-$0.35	-8.81%(-$0.03)
Q2 2025	Aug 13, 2025	-$0.29	-$0.30	-3.31%(-$0.01)

CATX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.10

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
CATXPerspective Therapeutics, Inc.	D	F	D	605.6x	-66.9%	23.0%	—	$2.17
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Perspective Therapeutics, Inc.

Perspective Therapeutics develops targeted radiopharmaceuticals using Lead-212, an alpha-emitting isotope designed to deliver radiation directly to cancer cells. The company's approach aims to improve treatment efficacy while reducing harm to healthy tissue. This technology addresses a significant market need for more selective cancer therapies across multiple tumor types.

CATX Next Earnings Report

Report dateNov 9, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.25

Revenue estimate$51,790

Also reporting on Nov 9, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

CATX Insider Transactions

SellSep 4, 2026
LANTHEUS ALPHA THERAPY, LLC
Beneficial Owner of more than 10% of a Class of Security
Shares: 247,932Value: $776,947
SellSep 2, 2026
LANTHEUS ALPHA THERAPY, LLC
Beneficial Owner of more than 10% of a Class of Security
Shares: 42,129Value: $131,219
SellSep 1, 2026
LANTHEUS ALPHA THERAPY, LLC
Beneficial Owner of more than 10% of a Class of Security
Shares: 35,769Value: $111,574
SellSep 1, 2026
LANTHEUS ALPHA THERAPY, LLC
Beneficial Owner of more than 10% of a Class of Security
Shares: 35,769Value: $111,574
SellAug 31, 2026
LANTHEUS ALPHA THERAPY, LLC
Beneficial Owner of more than 10% of a Class of Security
Shares: 78,145Value: $245,610

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

OCGNOcugen, Inc. Common StockBiological Products
XFORX4 Pharmaceuticals, Inc. Common StockBiological Products
ACBAurora Cannabis Inc. Common SharesPharmaceutical Preparations
IPSCCentury Therapeutics, Inc. Common StockBiological Products
LCTXLineage Cell Therapeutics, Inc.Biological Products
PALIPalisade Bio, Inc. Common StockBiological Products
FFFuture Fuel CorporationIndustrial Chemicals
YSGYatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary SharesCosmetics & Toiletries

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$1.96

High$6.16